[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"trastuzumab-deruxtecan\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:trastuzumab-deruxtecan":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,40],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100587471","trastuzumab-emtansinet-dm1-after-trastuzumab-deruxtecant-dxd-in-her2-positive-breast-cancer-in-korea-100587471",false,"NCT06928818","Trastuzumab Emtansine(T-DM1) After Trastuzumab Deruxtecan(T-DXd) in HER2-Positive Breast Cancer in Korea","Prospective Observational Study of Trastuzumab Emtansine Immediately After Trastuzumab Deruxtecan in Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in Korea","Inclusion Criteria:\n\n* HER2-positive, advanced (unresectable locally advanced or metastatic) breast cancer\n* Prior treatment with trastuzumab deruxtecan(T-DXd) in the advanced setting\n* Intention to treat with Trastuzumab Emtansine (T-DM1) as first therapy upon T-DXd progression\n\nExclusion Criteria:\n\n* Any systemic treatment, other than T-DM1, for breast cancer after trastuzumab deruxtecan (As an exception, patients treated with endocrine agents, not in combination with cytotoxics or antibody-drug conjugates, will be permitted in the study)\n* Has been previously treated with T-DM1 for advanced breast cancer\n* Has been previously treated with 4 or more lines of therapy for advanced breast cancer\n\n  * Half (50%) or more patients will be those who were treated with second-line trastuzumab deruxtecan (i.e. patients at the later line will be capped).","ALL","19 Years",{"count":19,"type":20},100,"ESTIMATED","OBSERVATIONAL","Prospective observational study of trastuzumab emtansine immediately after trastuzumab deruxtecan in patients with advanced HER2-positive breast cancer in Korea",[24,25,26],"Cancer of Breast","Trastuzumab Emtansine","Trastuzumab Deruxtecan","RECRUITING","2026-04-21",{"date":30,"type":31},"2026-04-23","ACTUAL",{"date":33,"type":31},"2025-02-26",{"date":35,"type":20},"2029-09-30",{"name":37,"class":38},"Seoul National University Hospital","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":47,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":39},"100614546","a-study-to-assess-the-efficiency-of-trastuzumab-deruxtecan-in-russian-breast-cancer-patients-100614546","NCT07281001","A Study to Assess the Efficiency of Trastuzumab Deruxtecan in Russian Breast Cancer Patients","Traderrus","Inclusion Criteria:\n\n1. Patients aged over 18 years old.\n2. Metastatic breast cancer included unresectable locally advanced breast cancer, de novo stage IV breast cancer, and recurrent metastatic breast cancer.\n3. Patients has received Trastuzumab Deruxtecan\n4. Available medical history.\n\nExclusion Criteria:\n\n1. Incomplete medical history.\n2. Pregnancy or breast-breeding","18 Years","80 Years",{"count":50,"type":20},60,"INTERVENTIONAL",[53],"NA","This multi-center observational retrospective study will collect real-world clinical data from eligible patients with unresectable or metastatic HER2+ breast cancer who have received one or more cycles Trastuzumab Deruxtecan in Russian Federation",[56,26],"HER2-positive Breast Cancer",[26,56],"2025-12-11",{"date":60,"type":31},"2025-12-15",{"date":62,"type":20},"2025-12",{"date":64,"type":20},"2026-05",{"name":66,"class":38},"Blokhin's Russian Cancer Research Center"]